Page 1 | Search Results | Blood | American Society of Hematology

1-8 of 8

Sort by

Sort Order Select

Journal Articles

Four Versus Two Years of Rituximab Maintenance (R-maintenance) Following Bendamustine Plus Rituximab (B-R): Initial Results of a Prospective, Randomized Multicenter Phase 3 Study in First-Line Follicular Lymphoma (the StiL NHL7-2008 MAINTAIN study)

Mathias J Rummel, Christian Buske, MD, Bernd Hertenstein, MD, Christian Lerchenmüller, MD, Michael Koenigsmann, MD, Elisabeth Lange, MD, Manfred Reeb, MD, Ulrich Kaiser, MD, Christina Balser, MD, Dirk Behringer, MD, Jan Dürig, MD, Tobias Gaska, MD, Georg Maschmeyer, MD, Georg Schliesser, MD, Alexander Christoph Burchardt, MD, Juergen Barth, Frank Kauff, Axel Hinke, PhD, Richard Greil, MD

Blood (2017) 130 (Supplement 1): 483.

https://doi.org/10.1182/blood.V130.Suppl_1.483.483

Published: 2017

Journal Articles

Prognostic value of circulating Bcl-2/IgH levels in patients with follicular lymphoma receiving first-line immunochemotherapy

Fabian Zohren, Ingmar Bruns, Sabrina Pechtel, Thomas Schroeder, Roland Fenk, Akos Czibere, Georg Maschmeyer, Dorothea Kofahl-Krause, Norbert Niederle, Gerhard Heil, Christoph Losem, Manfred Welslau, Wolfram Brugger, Ulrich Germing, Ralf Kronenwett, Juergen Barth, Mathias J. Rummel, Rainer Haas, Guido Kobbe

Blood (2015) 126 (12): 1407–1414.

https://doi.org/10.1182/blood-2015-03-630012

Published: 2015

Includes: Supplemental data

Journal Articles

Bendamustin-Rituximab Induction Followed by Observation or Rituximab Maintenance for Newly Diagnosed Patients with Waldenström's Macroglobulinemia: Results From a Prospective, Randomized, Multicenter Study (StiL NHL 7–2008 –MAINTAIN-; ClinicalTrials.gov Identifier: NCT00877214).

Mathias J. Rummel, MD, Christian Lerchenmüller, MD, Richard Greil, MD, Martin Görner, Manfred Hensel, MD, Erik Engel, Ulrich Jaeger, MD, Friedhelm Breuer, Bernd Hertenstein, Otto Prummer, MD, PhD, Christian Buske, MD, Juergen Barth, Alexander C. Burchardt, MD, Wolfram Brugger

Blood (2012) 120 (21): 2739.

https://doi.org/10.1182/blood.V120.21.2739.2739

Published: 2012

Journal Articles

Subanalysis of the StiL NHL 1–2003 Study: Achievement of Complete Response with Bendamustine-Rituximab (B-R) and CHOP-R in the First-Line Treatment of Indolent and Mantle Cell Lymphomas Results in Superior Survival Compared to Partial Response.

Blood (2012) 120 (21): 2724.

https://doi.org/10.1182/blood.V120.21.2724.2724

Published: 2012

Journal Articles

Bendamustine Plus Rituximab Versus Fludarabine Plus Rituximab In Patients with Relapsed Follicular, Indolent and Mantle Cell Lymphomas – Final Results of the Randomized Phase III Study NHL 2–2003 on Behalf of the StiL (Study Group Indolent Lymphomas, Germany)

Mathias J Rummel, MD, PhD, Ulrich Kaiser, MD, Christina Balser, Martina Beate Stauch, Wolfram Brugger, MD, PhD, Manfred Welslau, Norbert Niederle, Christoph Losem, Harald Ballo, Eckhart Weidmann, Ulrich von Gruenhagen, Lothar Mueller, Michael Sandherr, MD, Julia Vereschagina, Axel Hinke, Juergen Barth

Blood (2010) 116 (21): 856.

https://doi.org/10.1182/blood.V116.21.856.856

Published: 2010

Journal Articles

Peripheral Blood Stem Cell Mobilization After Bendamustine Containing Chemotherapy in Indolent Lymphomas Is Possible. Results From the Phase III Study of B-R Vs. CHOP-R (NHL 1-2003 trial) of the StiL (Study group indolent Lymphomas, Germany).

Christoph Alexander Burchardt, Wolfram Brugger, Georg Maschmeyer, Dorothea Kofahl-Krause, Lars Fischer, Fritz Roller, Juergen Barth, Mathias J Rummel

Blood (2009) 114 (22): 2679.

https://doi.org/10.1182/blood.V114.22.2679.2679

Published: 2009

Journal Articles

Quantitative Real-Time PCR of Peripheral Blood t(14;18) Positive Cells Predicts Treatment Response and Long-Term Outcome in Patients with Follicular Lymphoma.

Fabian Zohren, Ingmar Bruns, MD, PhD, Juergen Barth, Sabrina Pechtel, Roland Fenk, Thomas Schroeder, Akos G. Czibere, MD, Georg Maschmeyer, Dorothea Kofahl-Krause, Gerhard Heil, Norbert Niederle, Christoph Losem, Manfred Welslau, Ulrich Germing, Ralf Kronenwett, Rainer Haas, Mathias J Rummel, MD, PhD, Guido Kobbe, MD

Blood (2009) 114 (22): 441.

https://doi.org/10.1182/blood.V114.22.441.441

Published: 2009

Journal Articles

Bendamustine Plus Rituximab Is Superior in Respect of Progression Free Survival and CR Rate When Compared to CHOP Plus Rituximab as First-Line Treatment of Patients with Advanced Follicular, Indolent, and Mantle Cell Lymphomas: Final Results of a Randomized Phase III Study of the StiL (Study Group Indolent Lymphomas, Germany).

Mathias J Rummel, MD, PhD, Norbert Niederle, Georg Maschmeyer, Andre Banat, MD, MBA, Ulrich von Gruenhagen, MD, Christoph Losem, Gerhard Heil, Manfred Welslau, Christina Balser, Ulrich Kaiser, Harald Ballo, Eckhart Weidmann, Heinz A Duerk, Dorothea Kofahl-Krause, Fritz Roller, Juergen Barth, Dieter Hoelzer, MD, PhD, Axel Hinke, Wolfram Brugger

Blood (2009) 114 (22): 405.

https://doi.org/10.1182/blood.V114.22.405.405

Published: 2009

NARROW

Four Versus Two Years of Rituximab Maintenance (R-maintenance) Following Bendamustine Plus Rituximab (B-R): Initial Results of a Prospective, Randomized Multicenter Phase 3 Study in First-Line Follicular Lymphoma (the StiL NHL7-2008 MAINTAIN study)

Prognostic value of circulating Bcl-2/IgH levels in patients with follicular lymphoma receiving first-line immunochemotherapy

Bendamustin-Rituximab Induction Followed by Observation or Rituximab Maintenance for Newly Diagnosed Patients with Waldenström's Macroglobulinemia: Results From a Prospective, Randomized, Multicenter Study (StiL NHL 7–2008 –MAINTAIN-; ClinicalTrials.gov Identifier: NCT00877214).

Subanalysis of the StiL NHL 1–2003 Study: Achievement of Complete Response with Bendamustine-Rituximab (B-R) and CHOP-R in the First-Line Treatment of Indolent and Mantle Cell Lymphomas Results in Superior Survival Compared to Partial Response.

Bendamustine Plus Rituximab Versus Fludarabine Plus Rituximab In Patients with Relapsed Follicular, Indolent and Mantle Cell Lymphomas – Final Results of the Randomized Phase III Study NHL 2–2003 on Behalf of the StiL (Study Group Indolent Lymphomas, Germany)

Peripheral Blood Stem Cell Mobilization After Bendamustine Containing Chemotherapy in Indolent Lymphomas Is Possible. Results From the Phase III Study of B-R Vs. CHOP-R (NHL 1-2003 trial) of the StiL (Study group indolent Lymphomas, Germany).

Quantitative Real-Time PCR of Peripheral Blood t(14;18) Positive Cells Predicts Treatment Response and Long-Term Outcome in Patients with Follicular Lymphoma.

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only